Drawing for REJUVIQ

USPTO serial 87766080

REJUVIQ

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
REEVES, APRIL ELIZABETH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with REJUVIQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Laurence Rickles

Laurence Rickles TEVA PHARMACEUTICALS USA, INC.4oo Interpace ParkwayTRADEMARKS DEPARTMENTParsippany, NJ 07054

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals preparations for the prevention and treatment of central nervous system disorders; Pharmaceuticals preparations for the prevention and treatment of circulatory systems disorders; Pharmaceuticals preparations for the prevention and treatment of sensory organs disorders; Pharmaceuticals preparations for the prevention and treatment of urogenital organs disorders; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Contraceptive preparations; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Fertility enhancing preparations; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 10, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 10, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 3, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 1, 2020EX4GSOU EXTENSION 4 GRANTED—
Oct 1, 2020EXT4SOU EXTENSION 4 FILED—
Oct 1, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 8, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 6, 2020EX3GSOU EXTENSION 3 GRANTED—
Apr 6, 2020EXT3SOU EXTENSION 3 FILED—
Apr 6, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 4, 2019EX2GSOU EXTENSION 2 GRANTED—
Oct 4, 2019EXT2SOU EXTENSION 2 FILED—
Oct 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 6, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 4, 2019EX1GSOU EXTENSION 1 GRANTED—
Apr 4, 2019EXT1SOU EXTENSION 1 FILED—
Apr 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 9, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 14, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 14, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 25, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 9, 2018ALIEASSIGNED TO LIE—
Jun 23, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 8, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 7, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 7, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 25, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2018DOCKASSIGNED TO EXAMINER—
Feb 2, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 26, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance